Faron Pharmaceuticals: Positive FDA Feedback on Bexmarilimab - Redeye

Redeye is encouraged to learn that Faron has received positive FDA feedback and recommendations for the future development of lead candidate Bexmarilimab as a monotherapy in multiple solid tumors. We believe this is a great validation of Faron’s development plan for Bexmarilimab and the robust clinical data package generated through the MATINS trial.

Länk till analysen i sin helhet: https://www.redeye.se/research/890631/faron-pharmaceuticals-positive-fda-feedback-on-bexmarilimab?utm_source=finwire&utm_medium=RSS